Personalis (NASDAQ:PSNL) Sees Strong Trading Volume – What’s Next?

Personalis, Inc. (NASDAQ:PSNL) shares saw unusually-high trading volume on Friday . Approximately 6,060,111 shares traded hands during trading, an increase of 422% from the previous session’s volume of 1,161,555 shares.The stock last traded at $8.39 and had previously closed at $7.93.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Guggenheim lifted their price objective on shares of Personalis from $6.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. BTIG Research lifted their price target on Personalis from $11.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. HC Wainwright increased their price objective on Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Wednesday, October 8th. Finally, Morgan Stanley upped their target price on Personalis from $9.00 to $11.00 and gave the company an “equal weight” rating in a report on Monday, December 1st. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Personalis presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.57.

Personalis Stock Performance

The company has a 50 day moving average of $9.03 and a 200 day moving average of $6.98. The firm has a market cap of $759.24 million, a P/E ratio of -9.72 and a beta of 1.99.

Personalis (NASDAQ:PSNL) last posted its earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The firm had revenue of $14.50 million during the quarter, compared to analysts’ expectations of $13.31 million. As a group, analysts expect that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Insiders Place Their Bets

In other Personalis news, CFO Aaron Tachibana sold 103,668 shares of the stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the transaction, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at $1,772,857.24. This represents a 38.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Christopher M. Hall sold 29,612 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $8.99, for a total value of $266,211.88. Following the completion of the sale, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at $1,334,889.14. This represents a 16.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Personalis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PSNL. Legal & General Group Plc bought a new stake in shares of Personalis during the 2nd quarter worth $30,000. Ameritas Investment Partners Inc. bought a new stake in Personalis during the second quarter valued at about $34,000. BNP Paribas Financial Markets grew its position in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares during the last quarter. Focus Partners Wealth bought a new position in shares of Personalis in the first quarter worth about $47,000. Finally, Alpha Wealth Funds LLC acquired a new position in shares of Personalis during the 2nd quarter worth about $66,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.